Australia markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2996-0.0004 (-0.13%)
At close: 04:00PM EST
0.2950 -0.00 (-1.54%)
After hours: 07:37PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.3000
Open0.3000
Bid0.2910 x 1300
Ask0.3090 x 900
Day's range0.2951 - 0.3267
52-week range0.2580 - 9.1110
Volume293,474
Avg. volume753,222
Market cap5.492M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.0240
Earnings date12 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.00
  • Business Wire

    Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

    ATLANTA, November 29, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.

  • Business Wire

    Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

    ATLANTA, November 14, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia ("FM"), today announced financial results for the third quarter ended September 30, 2022, as well as plans to advance development of its lead antiviral development candidate, IMC-1, as a potential new treatment for FM patients.

  • Business Wire

    Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

    ATLANTA, November 03, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets. Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m. ET to discuss the result